OTOGUIDE: Precision you can see. You know OTOPLAN,* OTODRIVE,** and OTOARM. And now there’s OTOGUIDE, our new intraoperative software that enables you to see electrode array insertion like never before.
Clinicians and researchers can use the new “Quality of Life in People with Hearing Loss Questionnaire (HL-QoL)” to assess how hearing loss and treatment affect an individual’s quality of life. As the first validated questionnaire based on the WHO’s international classification of functioning, disability, and health, it is designed to assess hearing outcomes while providing a holistic perspective.
The early activation of cochlear implant audio processors is an option that growing numbers of hearing implant clinics now offer. This article summarizes recent publications on early activation in cochlear implantation and its reported impact on patient care, safety, impedance values, fitting parameters, audiological outcomes, complications, and more.
Stimulating the right pitch at the right rate and at the right place in the cochlea enables people with hearing loss to hear with their cochlear implants in a way that comes uniquely close to natural hearing. Simple, right? Not at all. MED-EL’s sophisticated technology that enables closest to natural hearing is anything but simple. Read on to find out what sets us apart from other CI manufacturers and why we are the worldwide leader when it comes to cochlear implant sound quality.
Prof. Dr. Philippe Lefèbvre and Prof. Dr. Joachim Müller share their experiences leading the feasibility study on MED-EL’s Totally Implantable Cochlear Implant (TICI), breakthrough technology that integrates all cochlear implant components—audio processor, microphone, and battery—into one device under the skin.
MED-EL has focused decades of research on residual hearing preservation. While remaining hearing is often limited to specific frequency ranges, preserving residual hearing can improve hearing outcomes with a cochlear implant.
.png)
